English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Epigenomics Licenses China Rights to Kindstar for Epi proLung

Jan. 9, 2014

Epigenomics AG, a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics, a leading Chinese clinical diagnostics company, announced on January 9, 2014 that both parties entered into a licensing and supply agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market.
Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.